bioAffinity Technologies (BIAF) EBITDA Margin (2022 - 2026)
bioAffinity Technologies (BIAF) posted quarterly EBITDA Margin of 267.62% for Q1 2026, down 12589.0% year-over-year from N/an in Q1 2025, and down 35.89% quarter-over-quarter from 196.94% in Q4 2025.
bioAffinity Technologies (BIAF) EBITDA Margin (2022 - 2026) Analysis & Trends
bioAffinity Technologies (BIAF) has reported EBITDA Margin for 5 consecutive years, with 267.62% the latest figure, recorded in Q1 2026.
- In Q1 2026, EBITDA Margin fell 12589.0% year-over-year to 267.62%; the TTM figure through Mar 2026 stood at 204.29% (down 9491.0% YoY), while the FY2025 annual figure was 171.58%, down 7594.0% from the prior year.
- EBITDA Margin retreated to 267.62% in Q1 2026 per BIAF's latest filing, from 196.94% in the prior quarter.
- Across five years, EBITDA Margin topped out at 80.84% in Q1 2024 and bottomed at 169160.69% in Q1 2023.
- Historically, EBITDA Margin has averaged 24179.53% across 5 years, with a median of 197.55% in 2025.
- Annual changes were most pronounced in 2024 — EBITDA Margin soared 16907986 bps — and 2026, when it slumped 12589 bps.
- bioAffinity Technologies' EBITDA Margin stood at 69213.17% in 2022, then jumped by 100 bps to 105.83% in 2023, then dropped by 26 bps to 133.47% in 2024, then sank by 48 bps to 196.94% in 2025, then sank by 36 bps to 267.62% in 2026.
- Business Quant data shows BIAF's EBITDA Margin at 267.62% in Q1 2026, 196.94% in Q4 2025, and 158.56% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Thermo Fisher Scientific | 234.15 Bn | 230.09 Bn | 8.34 Bn | 17.40% |
| 2 | Danaher | 152.10 Bn | 147.75 Bn | 3.61 Bn | 17.99% |
| 3 | Natera | 48.48 Bn | 47.38 Bn | 486.15 Mn | -10.07% |
| 4 | Agilent Technologies | 44.35 Bn | 42.55 Bn | 990.00 Mn | 21.74% |
| 5 | Iqvia Holdings | 43.68 Bn | 41.60 Bn | 1.44 Bn | 11.58% |
| 6 | Idexx Laboratories | 43.02 Bn | 42.83 Bn | 779.09 Mn | 34.98% |
| 7 | Illumina | 34.39 Bn | 33.22 Bn | 770.00 Mn | 21.14% |
| 8 | Mettler Toledo International | 28.29 Bn | 28.24 Bn | 650.22 Mn | 31.97% |
| 9 | Labcorp Holdings | 27.51 Bn | 27.37 Bn | 1.11 Bn | 12.10% |
| 10 | bioAffinity Technologies | 1.78 Mn | -649,139.45 | - | -219.24% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -219.24% |
| Mar 31, 2026 | -265.82% |
| Dec 31, 2025 | -194.59% |
| Sep 30, 2025 | -155.47% |
| Jun 30, 2025 | -194.65% |
| Mar 31, 2025 | -139.37% |
| Dec 31, 2024 | -131.53% |
| Sep 30, 2024 | -82.26% |
| Jun 30, 2024 | -85.40% |
| Mar 31, 2024 | -79.22% |
| Dec 31, 2023 | -98.32% |
| Sep 30, 2023 | -753.61% |
| Jun 30, 2023 | -8,903.38% |
| Mar 31, 2023 | -166,806.19% |
| Dec 31, 2022 | -68,902.77% |
| Sep 30, 2022 | -84,813.57% |
| Jun 30, 2022 | -52,382.77% |